Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery.
Nagakawa Y, Sahara Y, Hosokawa Y, Murakami Y, Yamaue H, Satoi S, Unno M, Isaji S, Endo I, Sho M, Fujii T, Takishita C, Hijikata Y, Suzuki S, Kawachi S, Katsumata K, Ohta T, Nagakawa T, Tsuchida A.
Nagakawa Y, et al. Among authors: nagakawa t.
Ann Surg Oncol. 2019 Jun;26(6):1629-1636. doi: 10.1245/s10434-018-07131-8. Epub 2019 Jan 4.
Ann Surg Oncol. 2019.
PMID: 30610555